文献速递心力衰竭与心肌病

4-羟基壬烯醛通过Dicer翻译后修饰损害心力衰竭中的miRNA成熟

4-Hydroxynonenal impairs miRNA maturation in heart failure via Dicer post-translational modification.
PubMed 文献 · Eur Heart J · 2023-01-01

本研究探讨4-羟基壬烯醛(4-HNE)在心力衰竭中的有害作用机制及潜在治疗。在大鼠和人类衰竭心脏中,4-HNE共价抑制Dicer,损害miRNA加工;通过Alda-1或AD-9308激活ALDH2增强4-HNE清除,可恢复Dicer活性、miRNA成熟并改善临床前模型的心功能。

要点

  • 4-HNE共价抑制Dicer,损害miRNA生物合成。
  • 衰竭心脏显示4-HNE清除缺陷和Dicer活性降低。
  • ALDH2激活可恢复Dicer活性并改善心功能。

核心结论

  • 4-HNE抑制Dicer直接损害心力衰竭中的miRNA生物合成,药理激活ALDH2降低4-HNE可恢复Dicer活性和miRNA成熟,可能成为心力衰竭的治疗策略。

研究设计与样本

  • 研究采用生化、功能和组化方法检测大鼠和人类衰竭心脏中的4-HNE加合物,并进行体外研究验证4-HNE靶点。
  • 使用三种不同病因的终末期人类衰竭心脏样本。
  • 在心力衰竭临床前模型中测试Alda-1及其口服生物可利用衍生物AD-9308的效果。

主要发现

  • 4-HNE以浓度和时间依赖方式与重组人Dicer发生分子间相互作用,破坏其活性和稳定性。
  • 二硫苏糖醇中和4-HNE或替换Dicer中4-HNE靶向残基可防止4-HNE对Dicer的抑制。
  • 终末期人类衰竭心脏显示4-HNE清除缺陷、Dicer活性降低和miRNA生物合成受损。
  • 通过Alda-1或AD-9308药理再激活ALDH2增强4-HNE清除,可恢复Dicer活性。
  • 在心力衰竭临床前模型中,ALDH2激活伴随miRNA成熟和心脏功能/重构改善。

临床怎么用

  • 药理激活ALDH2以降低心脏4-HNE水平,可能恢复Dicer活性和miRNA生物合成,作为心力衰竭的潜在治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Developing novel therapies to battle the global public health burden of heart failure remains challenging. This study investigates the underlying mechanisms and potential treatment for 4-hydroxynonenal (4-HNE) deleterious effects in heart failure. METHODS: Biochemical, functional, and histochemical measurements were applied to identify 4-HNE adducts in rat and human failing hearts. In vitro studies were performed to validate 4-HNE targets. RESULTS: 4-HNE, a reactive aldehyde by-product of mitochondrial dysfunction in heart failure, covalently inhibits Dicer, an RNase III endonuclease essential for microRNA (miRNA) biogenesis. 4-HNE inhibition of Dicer impairs miRNA processing. Mechanistically, 4-HNE binds to recombinant human Dicer through an intermolecular interaction that disrupts both activity and stability of Dicer in a concentration- and time-dependent manner. Dithiothreitol neutralization of 4-HNE or replacing 4-HNE-targeted residues in Dicer prevents 4-HNE inhibition of Dicer in vitro. Interestingly, end-stage human failing hearts from three different heart failure aetiologies display defective 4-HNE clearance, decreased Dicer activity, and miRNA biogenesis impairment. Notably, boosting 4-HNE clearance through pharmacological re-activation of mitochondrial aldehyde dehydrogenase 2 (ALDH2) using Alda-1 or its improved orally bioavailable derivative AD-9308 restores Dicer activity. ALDH2 is a major enzyme responsible for 4-HNE removal. Importantly, this response is accompanied by improved miRNA maturation and cardiac function/remodelling in a pre-clinical model of heart failure. CONCLUSIONS: 4-HNE inhibition of Dicer directly impairs miRNA biogenesis in heart failure. Strikingly, decreasing cardiac 4-HNE levels through pharmacological ALDH2 activation is sufficient to re-establish Dicer activity and miRNA biogenesis; thereby representing potential treatment for patients with heart failure.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kiyuna, Candido, Bechara, et al. 4-Hydroxynonenal impairs miRNA maturation in heart failure via Dicer post-translational modification. Eur Heart J. 2023. PMID: 37944136. doi:10.1093/eurheartj/ehad662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。